Apitope International NV, is proud to announce that Dr. Keith Martin, CEO of Apitope, has received the AstraZeneca, Business Development Professional of the Year Award 2008. David Brennan, CEO of AstraZeneca PLC, gave the award at the Pharmaceutical Licensing Group (PLG) Annual Awards Dinner 2009. (read more..)
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Experienced management with successful track-record
Innovative pipeline in large potential markets built on cutting-edge research:
- Lead product successfully completed Phase l/lla clinical trial in multiple sclerosis (MS) patients
- MS diagnostic blood test under development
- Therapeutic vaccine to prevent factor VIII inhibitor antibodies in haemophilia A patients under evaluation in pre clinical models
Patented, platform technology for identification of additional peptide-based
apitope
vaccines and diagnostics
Commercial agreements with global pharmaceutical companies
An exciting rapidly growing company with: